Aberrant high expression of immunoglobulin G in epithelial stem/progenitor-like cells contributes to tumor initiation and metastasis
Metrics: PDF 1428 views | HTML 1539 views | ?
Qinyuan Liao1,2,*, Wei Liu1,2,*, Yang Liu1,2,*, Fulin Wang4, Chong Wang1,2, Jingxuan Zhang3, Ming Chu1,2, Dongyang Jiang1,2, Lin Xiao1,2, Wenwei Shao1,2, Zhengzuo Sheng1, Xia Tao5, Lei Huo6, C. Cameron Yin7, Youhui Zhang8, Gregory Lee9, Jing Huang1,2, Zihai Li10, Xiaoyan Qiu1,2,3
1Department of Immunology, School of Basic Medical Sciences, Peking University, Beijing, 100191, China
2Peking University Center for Human Disease Genomics, Beijing, 100191, China
3Key Laboratory of Medical Immunology, Ministry of Health, Beijing, 100191, China
4Department of Pathology, Chinese PLA General Hospital, Beijing, 100853, China
5Department of Gynecology, Peking University First Hospital, Beijing, 100034, China
6Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA
7Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA
8Department of Immunology, Cancer Institute & Hospital, Chinese Academy of Medical Science, Beijing, 100021, China
9Andrology Lab, University of British Columbia Centre for Reproductive Health, Vancouver, BC V5Z 4H4, Canada
10Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC 29425, USA
*These authors have contributed equally to this work
Xiaoyan Qiu, e-mail: email@example.com
Keywords: IgG, RP215, epithelial stem/progenitor-like cells, tumor metastasis
Received: July 05, 2015 Accepted: October 02, 2015 Published: October 12, 2015
High expression of immunoglobulin G (IgG) in many non-B cell malignancies and its non-conventional roles in promoting proliferation and survival of cancer cells have been demonstrated. However, the precise function of non-B IgG remains incompletely understood. Here we define the antigen specificity of RP215, a monoclonal antibody that specifically recognizes the IgG in cancer cells. Using RP215, our study shows that IgG is overexpressed in cancer cells of epithelial lineage, especially cells with cancer stem/progenitor cell-like features. The RP215-recognized IgG is primarily localized on the cell surface, particularly lamellipodia-like structures. Cells with high IgG display higher migration, increased invasiveness and metastasis, and enhanced self-renewal and tumorgenecity ability in vitro and in vivo. Importantly, depletion of IgG in breast cancer leads to reduced adhesion, invasion and self-renewal and increased apoptosis of cancer cells. We conclude that high expression of IgG is a novel biomarker of tumor progression, metastasis and cancer stem cell maintenance and demonstrate the potential therapeutic benefits of RP215-recognized IgG targeted strategy.
Immunoglobulin (Ig) genes were evolved approximately 500 million years ago and exist in nearly all classes of jawed vertebrates. To date, almost all of the significant findings in the field have centered on B cell-derived Ig (B-Ig). We have first reported that a variety of non-B cells, such as breast, liver and lung cancer cells, but not their normal counterpart, surprisingly express high level of IgG . Our following studies demonstrated that the IgG expressed in cancer cells has the ability to promote tumor cell growth . Subsequently, our and other groups have found that many forms of Igs, including IgG, IgA, and IgM (known as non-B-Igs) are widely expressed in non-B-cells of different origins, especially cancer cells [3–13].
To recognize a variety of antigens, the Ig gene is rearranged to yield a vast repertoire of antigen receptor-binding specificities during B cell development. This process involves two stages of rearrangement, with the first being the assembly of the variable (V), diversity (D), and joining (J) gene segments of the heavy chain (IgH) and the V and J gene segments of the light chain (IgK). Rearrangement enables B-Igs to display a great diversity in an individual. We have analyzed sequences of thousands of non-B-Igs genes from isolated epithelial cells, neuron, and spermatogenic cells in human and mouse [14–17]. Clearly, all of non-B-Igs also display classical VHDJH and VκJκ recombination, however, comparing to B-Igs, the non-B-Igs display several unique genetic characteristics. Firstly, cells of the same linage from an individual, even from different individuals, frequently use several conserved sets of VHDJH and VκJκ rearrangements [14, 15]. Secondly, the VHDJH rearrangements of different classes of IgH, such as gamma chain of IgG and mu chain of IgM, in the same cell show their own special VHDJH pattern . These indicate that a non-canonical mechanism of class switch recombination is present in non-B cells, and each class of Ig in the same cell may exert their own specific functions. Thirdly, VH in cancer cells usually exhibits hypermutation, while VH region keeps the germline sequence in normal cells , suggesting that the VH hypermutation may be involved in tumorgenesis.
Previous studies from our and other groups demonstrated that IgG is prominently overexpressed in many cancers [2–12], but expressed at a very low level in their normal counterparts. In addition, IgH gene copy number is significantly increased in rat breast cancer induced by chemical carcinogen . Furthermore, IgG expression level is positively correlated with low differentiation of cancer cells [18, 19]. Importantly, cancer cell-derived IgG promotes cancer cell proliferation and survival in vitro and in vivo [2, 20]. Yet, the precise effect of non-B-IgG in cancer initiation and progression remain elusive.
RP215, a monoclonal Ab, react with ovarian cancer cells using the extract of the ovarian cancer cell line OC-3-VGH as an immunogen . It was shown that RP215 also reacts with human cancer cells of many other tissue origins but does not react with cells from normal tissues . The molecule recognized by RP215 is known as CA215 (cancer antigen 215) and has been considered as a pan cancer marker. CA215 is later identified as IgG, and sialic acid has been reported to be enriched in the RP215-affinity purified IgG [23, 24]. Moreover, RP215 is able to induce extensive apoptosis and significantly inhibit tumor growth in vivo [25, 26]. Taken together, we decided to explore the function of cancer-derived IgG using RP215 as a tool.
In this study, we identify that RP215 recognized IgG is prominently expressed in cancer cells of epithelial lineage, especially those with stem/progenitor-like cancer cell features. RP215 recognized IgG is involved in tumor initiation and progression by maintaining cancer stem cell features and promoting metastasis.
RP215 specifically recognizes IgG
To identify the specificity of RP215 antibody, Western blot, affinity chromatography and mass spectrometry (MS) were performed using the whole cell lysate containing all cancer cell proteins. We determine that RP215 recognizes a single band of IgG heavy chain in cancer cell extracts from EpCAM (epithelial cell adhesion molecule)-positive cancer cells isolated from ascitic fluid of ovarian cancer patients, as well as several cancer cell lines, including breast cancer (MDA-MB-231 and MCF-7), prostate cancer (PC3) and lung cancer (A549) (Figure 1A a and 1A b). Moreover, we found that the IgG recognized by RP215 was high expressed in kidney cancer cells isolated from patient tissues, but few in the normal renal tubular epithelial cells from tumor adjacent of renal tissues (Figure 1A c). Knockdown of IgG heavy chain by RNA interference results in a reduction of IgG heavy chain band recognized by RP215 (Figure 1A d). Additionally, only IgG, but not other proteins in cancer cells, is affinity-purified by RP215 shown by SDS-PAGE, Western blot and mass spectrometry (Figure 1B). To address if the IgG recognized by RP215 has some unique patterns, we analyzed the VDJ pattern in several cancer cell lines, including MDA-MB-231, MCF-7 and SK-MES-1 (lung squamous cell carcinoma), recognized by RP215. The sequencing analyses show that each cancer cell line-derived IgG heavy chain has its own VDJ pattern, such as VH3-7/DH3-3/JH5 in MDA-MB-231, VH4-4/DH2-21/JH4 in MCF-7 and VH4-59/DH2-15/JH4 in SK-MES-1, suggesting that RP215 recognition is unrelated to any unique VDJ patterns and that the specific epitope recognized by RP215 should be a common epitope of cancer-IgG heavy chains.
Figure 1: IgG is recognized by RP215. A. (a) The IgG was detected in purified human IgG (left, IgG, as positive control) and in cancer cell extracts of EpCAM-positive cancer cells isolated from ascitic fluid from patients with ovarian cancer (right, lysate) by Western blot using RP215, the commercialized anti-human IgG antibody as a control; (b) RP215 recognized IgG was detected in the cell lysate of several cancer cell lines respectively (MDA-MB-231, MCF-7, PC3 and A549); (c) IgG recognized by RP215 was detected in kidney cancer cells isolated from patient tissues and normal renal tubular epithelial cells from tumor adjacent of renal tissues; (d) IgG expression was determined after treatment with two siRNAs targeting the IgG heavy chain by Western blot analysis. NC as control siRNA. GAPDH was used as an internal control. B. By RP215-affinity chromatography, IgG in EpCAM+ cancer cells isolated from ascitic fluid was purified and analyzed by SDS-PAGE, Western blot and MS analysis. (a) The protein purified by RP215-affinity chromatography showed 55kDa, lane 1: the first tube of elution, lane 2: the last tube of elution, by SDS-PAGE; (b) the protein was determined by Western blot under non-reduced (150kDa) or reduced SDS-PAGE condition; (c) The 55kDa band was identified by MS analysis, and the peptide sequences high homologous to the VH3 family of Ig heavy chain are marked in red.
Overexpression of RP215-recognized IgG in epithelial cancer cells, but not in B lymphoid or mesenchymal originated cancer cells
RP215 recognizes many epithelial cancer cells , but much less is known about the detail expression profile of RP215-recognized epitope. we analyzed expression profile and distribution of RP215-recognized IgG in malignant cells, including epithelial, lymphoid and mesenchymal tissues. The immunohistochemical results revealed that the IgG is shown in almost all epithelial cancers including breast, prostate, colon, lung, gastric, ovarian and esophageal carcinomas. Unexpectedly, a low concentration of RP215 gave rise to a significant RP215 staining (IgGhigh) in a small population of basal/myoepithelial (which are considered to be adult stem/progenitor cells)-like cells , in the interior spaces of carcinoma cell layers, or in some invasive single or multiple clusters between 4–10 cancer cells (Figure 2A). Suggest that expression of IgG recognized by RP215 might be related to cancer cell regeneration, migration and invasion. No staining has been observed in lymphoid or mesenchymal originated tissues with the exception of a population of epithelial-like cancer cells in synovial sarcoma or epithelioid sarcoma (Figure 2B, Supplementary Table S1). These results suggest that RP215 mainly recognizes epithelial cancer cells, especially the epithelial CSC-like cells, but not those cells of non-epithelial origin.
Figure 2: IgG recognized by RP215 was mainly limited to be expressed in some epithelial lineage of cells, especially stem cell-like cells. A. RP215 expressed in human epithelial cancer tissues. Strong immunostaining was showed in a small population of basal/myoepithelial-like cancer cells of breast, colon, lung, and prostate (black arrows). And the cancer cells at the front of invasive tumors in esophagus cancer, breast cancer and gastric cancer (black arrows). Red arrows indicated for the cancer cells in the gastric cancer in situ. Scale bars, 100 μm. B. No immunostaining was observed in lymphomas or mesenchymal tumors, except for some cells with epithelial feature in synovial sarcoma, epithelioid sarcoma and mesothelioma. Scale bars, 50 μm.
Subsequently, we first analyzed expression profile of RP215-recognized IgG in normal tissues by immunohistochemical staining using RP215. The results show that RP215 is unable to react with normal tissues of multiple origins such as liver, kidney, lung, cervix, pancreas and endometria, brain, lymphocytes and mesenchymal cells. Only a small number of epithelial cells showed positive staining in the stomach, small intestine, thymus, and bile duct. Exceptionally, very strong RP215 staining is displayed in squamous cells, contained in the skin, esophagus and cervix, and some basal layer/myoepithelial cells, located in the breast glands, prostatic glands, bronchial epithelia and bronchial glands. No staining was seen with the luminal cells (Supplementary Figure S1). The unique immunostaining pattern of RP215 did not report in previous studies.
IgGhigh cells co-localize with CSCs as well as adult stem/progenitor cells of epithelial origins
The CD44+/CD24−/low cells are a subset of breast cancer stem cells (BCSCs) [28–30]. We first used the breast cancer as a model to analyze the correlation between IgGhigh cells and CD44+/CD24−/low BCSCs on adjoined sections by immunohistochemistry using RP215 and anti-human CD44v6, a CD44 isoform, which is more correlate to tumor invasion . Our results clearly indicated a strong positive correlation and co-localization between RP215high cells and CD44v6+ cells in the basal-like or invasive cancer cells (correlation coefficient R = 0.6794, P = 4.53 × 10−9, n = 58), but no correlation or co-localization was found between IgGhigh cells and CD24+ cells (Supplementary Figure S2A). Importantly, a stronger correlation has been found between IgGhigh cells and CD44v6+ cells in infiltrating ductal carcinoma (R = 0.8677, P = 1.49 × 10−6, n = 19) than in ductal carcinoma in situ (R = 0.4076, P = 1.00 × 10−2, n = 39) (Figure 3A and 3B). Furthermore, these basal-like cells, invasive cancer cells and cells at the leading edge of cancer show a higher frequency of RP215 staining than those of anti-CD44v6 staining (Figure 3C). Suggest that RP215-recognized IgG may be more correlation with BCSCs than that of CD44V6. Both CD133 and ALDH1 are also considered as BCSC markers, which are considered to be different subpopulation of BCSC from CD44+/CD24− BCSCs [32–33]. We also analyzed correlations between RP215high cells and CD133 and ALDH1. No significant correlation was found between either IgGhigh cells and CD133 or IgGhigh cells and ALDH1 (Supplementary Figure S2B). These observations suggest that RP215 mainly recognizes the subpopulation of CD44+/CD24− BCSCs.
Figure 3: RP215high cells displayed co-localization with CSCs. A. RP215high cells was co-expressed with CD44v6. The results indicated the correlation between RP215high cells and CD44v6+ cells in infiltrating ductal carcinoma (a), and in ductal carcinoma in situ (b). R, Pearson correlation coefficient. B. The relationship between RP215high cells and CD44v6+ cells in basal-like cells in breast cancer tissues was analyzed by immunohistochemistry (black arrows). Scale bars, 50 μm. Comparing the pathological scores between RP215high cells and CD44v6+ cells in infiltrating ductal carcinoma (a) and in ductal carcinoma in situ (b). C. The relationship between RP215high cells and CD44v6+ cells in invasive cancer cells in breast cancer tissues was analyzed by immunohistochemistry. Scale bars, 50 μm. Strong immunostaining of RP215 was shown in a small population of CSC-like cancer cells and some frontier cancer cells in breast cancer tissues (demarcated by red line and black arrows), more specific staining for the invasive cancer cells was showed by RP215 than that by anti-CD44, the significant differences are displayed in the column (on the right).
In general, tumor initial cells (TICs)/cancer stem cells (CSCs) display similar characteristics and markers as their normal lineage-restricted stem/progenitor cells. p63, which is a well-accepted lineage-restricted stem/progenitor cell marker of stratified epithelium  As expected, our results show that strong RP215 staining in squamous cells (which is described to have the properties of restricted stem/progenitor cells), and in basal/myoepithelial cells of stratified epithelium, and co-localizes with p63. However, almost no staining was found in differentiated epithelial cells (Supplementary Figure S2C). Indicate that RP215-recognized IgG is also overexpressed in adult stem/progenitor cell of stratified epithelium, but not the differentiated cells.
Increasing RP215-recognized cells in breast tissue predicted metastasis and correlate with poor prognosis factors
We first analyzed the significance of RP215 reactivity in the evaluation of cancer metastasis using a TMA including 45 pairs of breast cancer and their lymph node metastases. We found that much stronger staining was observed in the metastatic cancer cells than in situ breast cancer (Figure 4A and 4B). Furthermore, using 107 cases of breast cancer, we analyzed the significance of RP215 staining in clinical prognosis as compared with several well-accepted prognostic indicators. The estrogen receptor (ER), progesterone receptor (PR), PS-2 (an regulated protein of estrogen) and nm23 (a tumor metastasis inhibitory gene) have been considered good prognostic indicators in breast cancer [35–37]. as well as human epidermal growth factor receptor 2 (Her-2), an independent prognostic factor for poor prognosis of breast cancer, and P-glycoprotein (P170) have been associated with poor prognosis  Our results clearly showed that strong RP215 staining was negatively correlated with the expression of PR (P = 0.013), PS-2 (P = 0.002), and nm23 (P = 0.037). As expected, RP215 staining was positively correlated with Her-2 (P = 0.008) and P170 (P = 0.051). However, RP215 staining did not correlate with the expression of Ki-67, a marker of cell proliferation (P = 0.736), or topoisomerase II, another indicator of poor prognosis  (P = 0.297) (Figure 4C).
Figure 4: Expression frequency of RP215-positive cells was significantly high in metastatic cancers, which predicted metastasis and poor prognosis. A. and B. The RP215 expression level in 45 matching pairs of breast cancer tissues and their corresponding lymph node metastases was analyzed by immunohistochemistry. Scale bars, 50 μm. Error bars show means ± standard error. **P < 0.005 by the Student t-test. C. The correlation between RP215 and several well-accepted prognostic indicators of breast cancer. Strong RP215 staining was negatively correlated with the expression of PR (P = 0.013), PS-2 (P = 0.002), and nm23 (P = 0.037), while positively correlated with Her-2 (P = 0.008) and P170 (P = 0.051). RP215 staining did not correlate with Ki-67 (P = 0.736) or topoisomerase II (P = 0.297). **P < 0.005 by the Student t-test.
IgGhigh cells displayed high migration, metastasis and CSCs-like characteristics
To further confirm the involvement of RP215-recognized IgG in the properties of CSCs, we have analyzed the frequency of RP215 staining on cell surface between MDA-MB-231 (a claudin-low breast cancer cell-line, which was described for their properties of CSCs) and MCF-7 (a luminal-like breast cancer cell-line, which was described for their limited abilities to proliferate and migrate) [40–41] by fluorescence-activated cell sorting (FACS). It was found that higher percentage of RP215-recognized cells was found in MDA-MB-231 than in MCF-7. Next, the IgGhigh and IgG-/low cells of MDA-MB-231 and MCF-7 cells were sorted by FACS (Supplementary Figure S3). Initially, in MDA-MB-231, but not in MCF-7, we found that IgGhigh cells displayed a greater ability to proliferate, migrate and invade as compared with IgG-/low cells (Figure 5A–5E) by CCK8, clone formation, wound healing, Transwell, and transwell inserts coated with matrigel matrix assay. Moreover, the expression of E-cadherin (CDH1), a negative-related protein for tumor invasion, was clearly reduced, and two positive-related proteins for tumor invasion and metastasis, MMP-2 and MMP-9 , were increased in expression in the IgGhigh MDA-MB-231 cells (Figure 5F).
Figure 5: To confirm the involvement of RP215high in the properties of CSCs in sorted RP215high MDA-MB-231 or MCF-7 Cell, the proliferation, division, migration, invasion capacity, as well as the mammospheres formation, drug resistance to chemotherapy drugs, and the tumor initiation and metastasis capacity were determined in vivo, compared with the RP215-/low cells. A. and B. Proliferation of RP215high MDA-MB-231 cells was detected by CCK8 and clone formation assay. C. The migration ability of RP215high MDA-MB-231 cells was analyzed by wound-healing. Images were taken at 0, 24, and 48 h. D. The migration ability of RP215high MDA-MB-231 or MCF-7 cells was analyzed by Transwell assay. Data were taken 24 h in MDA-MB-231, and 96 h in MCF-7. E. The invasion capacity of RP215high MDA-MB-231 cells was detected in Transwell inserts coated with matrigel matrix. Images were taken at 48 h. F. Expression level of CDH1, MMP-2 and MMP-9 was determined in RP215high MDA-MB-231 cells by qRT-PCR. G. Mammospheres were generated from 10,000 RP215high MDA-MB-231 or MCF-7 cells sorted by FACS in suspension culture, and then counted. H. Drug resistance capacity of RP215high MDA-MB-231 or MCF-7 cells to paclitaxel was analyzed by CCK8 assay. I. Division ability of RP215high MDA-MB-231 single cell was analyzed by continuous cell passage for 35 days. J. The number of outgrowths generated in NOD/SCID mice fat pads by RP215-/low and RP215high MDA-MB-231 cells. a, for the 1st experiment; b, for the 2nd experiment. K. a, representative tumor grown in NOD/SCID mice at the RP215high cells’ injection site. No tumor was detected at the RP215−/low cells’ injection site. b & c, H & E staining of RP215high cells’ injection site, revealing presence of tumor cells (c), the RP215−/low cells’ injection site contained only mouse tissue (b). Scale bars, 50 μm. L. The metastatic potential of sorted RP215−/low and RP215high MDA-MB-231 cells to liver was observed by spontaneous metastasis assays in vivo. RP215−/low and RP215high MDA-MB-231 cells (1 × 106) were subcutaneously injected into the right mammary fat pad of 6-week-old female BALB/c nude mice. After 6 weeks, the mice were sacrificed and dissected. And the metastatic tumors in liver were pathologically examined, and these livers were weighted and data was analyzed. Error bars show means ± standard errors from individual experiments with three replicate assays. *P < 0.05; ** P < 0.01; ***P < 0.001 by the Student t-test.
To further analyze if IgGhigh cells have CSC-like properties, we first performed sphere formation and drug-resistance assays to determine their self-renewal and drug-resistance abilities in vitro. IgGhigh MDA-MB-231 cells displayed significantly higher sphere-forming efficiency and resistance to paclitaxel than that of IgG−/low cells. However, no obvious difference in these properties was observed when comparing IgGhigh and IgG−/low MCF-7 cells (Figure 5G and 5H). In addition, CSC has a great division potential. Subsequently, we have compared clone formation and division potential between IgGhigh and IgG−/low MDA-MB-231 cells dependent on the single cell clone formation assay, it was found that both IgGhigh cell and IgG−/low cell could come into being cell clones, however, IgGhigh cell clones show a rapid growth ability than IgG−/low cells. To compare the division potential between IgGhigh and IgG−/low MDA-MB-231 clones. We selected 3 independent IgGhigh and 3 independent IgG−/low MDA-MB-231 clones, and continuously culture in vitro for 36 days. Observably, this analysis showed a rapid division frequency in all of IgGhigh clones, while 3 IgG−/low MDA-MB-231 clones showed limited divide ability, or slow growth (Figure 5I), moreover, after cryopreservation, the IgG−/low clone, but not IgGhigh clones, lost their division and growth ability. In addition, we analyzed the expression level of IgG heavy chain in MDA-MB-231 cells cultured in 3D soft fibrin gel, an ideal method to prepare CSCs , for 5 days. Obviously, compared to conventional cultured MDA-MB-231 cells, the MDA-MB-231 cells cultured in 3D soft fibrin gel showed overexpression level of IgG heavy chain (data not shown). This results indicated that IgGhigh cells has higher potential of stem/progenitor cells than IgG-/low cells.
To confirm that RP215high cells have tumor initiating abilities, purified RP215high and RP215-/low cells from MDA-MB-231 were used to perform tumorogenicity assays in NOD/SCID mice. As shown in Figure 5J and 5K, as few as 500 purified RP215high cells initiated tumor formation in transplanted mice, but no or few tumor formation was found in NOD/SCID mice transplanted by the parental RP215−/low cells. In addition, to further confirm the IgG link to potential of stem/progenitor cells, we have purified the 500 IgGhigh cells and IgG−/low cells from the graft tumor, which were used to perform tumorogenicity assays in NOD/SCID mice. As shown in Figure 5J, the IgGhigh cells showed higher initiated tumor formation ability than that of IgG−/low cells. We further compared the metastatic property between IgGhigh cells and IgG−/low MDA-MB-231 cells in nude mice after sub-cutaneous injection. These results showed that the IgGhigh cells had higher metastasize capacity to the liver than IgG−/low cells (Figure 5L). Expectedly, some nude mice that were injected with “IgGhigh” cells were often accompanied by ascites, pleural hemorrhage, blindness and short survival times. However, none of these phenomena were observed in mice adoptively transferred with IgG−/low cells (Supplementary Figure S4). These findings suggested that the IgGhigh cells have a much greater metastatic potential.
RP215 recognized IgG is essential for the anchorage of cancer cells to extracellular matrix or adhere between cells, knockdown of IgG reduces proliferation, self-renewal, migration and invasion of MDA-MB-231 cells
We have investigated sub-cellular localization of RP215-recognized IgG in several cancer cell lines, including HT-29 (colon cancer), MDA-MB-231 and MCF-7. Immunofluorescence results show that RP215 staining mainly showed on the cell surface, but the staining degree showed considerable variations among cancer cells of the same cancer cell line. Notably, the RP215 staining on cancer cell surface displayed significantly pseudopodia-like structure, which extended to the extracellular matrix or adjacent cells (Figure 6A). We synthesized two siRNAs that targeted the constant region of the IgG heavy chain and transfer it to MDA-MB-231(Figure 6B). We found that when knockdown of IgG abolished the anchoring of cancer cells to extracellular matrix, and resulted in cell membrane rolling up (Figure 6C) in the 3D culture. Importantly, the CSC characteristics, such as self-renewal, proliferation, migration, and invasion were eliminated (Figure 6D–6I). Furthermore, less of the IgG significantly enhanced the expression of CDH1 and reduced the expression of MMP-2 and MMP-9 (Figure 6J). In addition, to test the specificity of the siRNAs, the siRNA1 and siRNA2 were mutated (the 9th–12th base sequence were reversed, and named con-siRNA1 and con-siRNA2, respectively), and used as a control. As expected, these cell characteristics and phenotype as described above were specifically eliminated by siRNA1 and siRNA2, but not by con-siRNA1 or con-siRNA2 in MDA-MB-231 cells (Supplementary Figure S5).
Figure 6: Sub-cellular localization of IgG showed on cancer cell surface, knockdown of IgG by siRNA targeting the heavy chain constant region of IgG reduces proliferation, migration, and invasion of the MDA-MB-231 cells. A. By immunofluorescence staining, RP215-recognized IgG significantly showed on cell membrane (red arrow) filamentous junction between cancer cells (orange arrow), and pseudopodia-like structure (yellow arrow) in HT-29, MDA-MB-231 and MCF-7. Scale bars, 25 μm. B. IgG expression was determined after treatment with two siRNAs targeting IgG heavy chain, by Western blotting. NC as control siRNA. C. Morphological changes of MDA-MB-231 cells when knockdown IgG in 3D culture system (72 h) by Rhodamine-phalloidin staining for F-actin. Scale bars, 24 μm. Color: red (F-actin), blue (nuclei). D. Mammospheres formation after replanting of 10,000 MDA-MB-231 cells. Cell proliferation E. and colony formation F. was analyzed after treatment with IgG siRNA by CCK8 and colony formation assays. Migration ability of MDA-MB-231 cells was analyzed after treated with the IgG siRNA by wound-healing G. and Transwell assays H. Images were taken at 0, 24, and 48 h in wound heal assays and 24 h in Transwell assay. I. Invasion ability of MDA-MB-231 cells was analyzed after treated with the IgG siRNA on Transwell inserts coated with matrigel matrix. Images were taken at 48 h. J. Expression level of CDH1, MMP-2 or MMP-9 was detected after treated with the IgG siRNA by qRT-PCR. Error bars show means ± standard errors from individual experiments with three replicate assays.
In this report, using RP215, a mAb specifically recognizing IgG heavy chain expressed in non-B cancer cells, we identified the RP215-recognized IgG, which was significantly expressed in epithelial lineage cells and was enriched in CSCs and adult stem/progenitor-like cells of the epithelial tissues. These IgG was found to be significantly associated with increased tumor initiation, migration, metastasis, and maintenance of CSCs feature, suggesting that the RP215-recognized IgG showed the function as a novel oncogene, which showed a potential for cancer therapy as a novel target of many epithelial cancers.
RP215 is a smart antibody for the recognition of epithelial cancer cell-derived IgG. In previous studies, almost all of observations about cancer cell-derived IgG at protein level was according to the finding by some commercialized anti-IgG antibody [1–12] using circulating IgG as an antigen. Those antibodies do not discriminate B cell-derived IgG from cancer cell-derived IgG. So to obtain specific antibody for the non-B-IgG is essential to findings of unique structure and function of non-B-IgG. Although it has been reported that RP215 recognizes cancer-IgG, it was questioned if RP215 may also recognize other proteins. In this study, we have further identified the specific of RP215. Our results clearly show that RP215 only recognizes a single 55 kDa IgG heavy chain in the whole cell lysate of cancer cells. This conclusion was supported by SDS-PAGE, Western blot and mass spectrometry analysis and was confirmed genetically by RNA interference of IgG. Thus, we can give a conclusion that RP215 only recognizes IgG, but not other proteins. Importantly, RP215 only recognized a portion of IgG subspecies of circulating IgG, but not the majority of circulating IgG. These results suggest that RP215 seem mainly recognize the non B cell-derived IgG, which may be used to discriminate the source of IgG between that from B cells and non B cells.
RP215-recognized IgG can serve as a novel target for therapy of most epithelial cancers, as well as which can also use for identification of epithelial cancer stem cells. RP215 have been reported to recognize many tissue origins, but not in normal cells. Moreover, RP215 displayed a great potential for cancer therapy [21, 25]. Actually, the detail expression profile of IgG recognized by RP215 still remains unclear. In this study, we first analyzed the expression profile of IgG in many epithelial, mesenchymal and lymphoid lineage of either normal or malignant cells by Immunohistochemistry. The results revealed that in the cancer tissues, RP215-recognized IgG was significantly expressed in almost all epithelial cancers, especially overexpression in a small population of epithelial CSC-like cells. Obviously, but not in either lymphoid or mesenchymal originated cancers. In normal tissues, RP215 staining did not found in almost differentiated cells, except for a small population of adult stem/progenitor cells like stem cells and squamous cells. This finding suggests that RP215-recognized IgG can serve as a novel target for therapy of almost epithelial cancers, as well as which can also use for identification of epithelial cancer stem cells. in view of the fact that RP215-recognized IgG can be found in some normal adult stem/progenitor cells like a stem cells and squamous cells, it is worth emphasizing that we have tried to determined the anti-cancer effect and safety of RP215 in vivo, we found that RP215 displayed a significance anti-cancer effect (data not shown), furthermore, the use of RP215 did not cause damage of trachea, breast, stomach, intestine and liver, in addition to epidermal desquamation (data not shown).
RP215-recognized IgG is involved in cancer initiation and metastasis. Cancer stem cells are cancer cells that possess characteristics associated with normal stem/progenitor cells, specifically the ability to give rise to all cell types found in a particular cancer sample, CSCs are therefore tumorigenic . In this study, we have discovered that RP215-recognized IgG was overexpressed CSC-like cells such as CD44+/CD24−/low of breast cancer cells, and the p63+ adult stem/progenitor cells of many stratified epithelium. Furthermore, we found that in breast cancer cell line, MDA-MB-231, IgGhigh cancer cells displayed properties of CSCs, such as self-renewal, drug resistance, highly capacity of division, invasion, metastasis in vitro, and tumorigenicity in NOD/SCID mice. In contrast, knockdown of IgG heavy chain significantly reversed these phenotype described as above. More importantly, we also found that IgG heavy chain was significantly increased in the MDA-MB-231 cells cultured in 3D soft fibrin gel, an ideal method to prepare CSCs . These functional studies suggest that RP215-recognized IgG may play significant roles in tumor initiation and maintenance of CSCs. In addition, in the breast carcinomas, how to understand why the RP215-recognized IgG mainly correlated with the basal-like-origin of MDA-MB-231 of BCSC that show CD44+/CD24−/low, but not with the luminal-like breast cancer cell line MCF-7 of BCSC as well as the CD133+ or ALDH1+ BCSC. Currently, we can not give an explanation. It has been considered that CD44+/CD24−/low cells or P63+ cells were mainly associated with the CSCs of basal cell origin of ductal carcinoma, however, the characteristics and markers of luminal cell-derived breast cancer CSCs remains unclear. In view of IgG expression was highly correlated with CD44+/CD24−/low cells, we believe the IgG functions that promoting cancer genesis and metastasis are mainly association with CSCs of basal cell origin. However, it remains unclear why IgG expression was no such correlation with CSCs properties of luminal cell origin although the IgG can be also expressed in luminal cell origin of cancer cells as MCF-7.
In addition, we found that the RP215-recognized IgG was significantly located on membrane of cancer cell, especially on its pseudopodia, an essential subcellular structure for cell migration and invasion. RP215high cancer cells displayed high ability of migration and metastasis. Loss of IgG abolished the anchoring of cancer cells to extracellular matrix, causing cell membrane rolling up, reducing cell migration and invasion, and inducing apoptosis. We suggest that expression of highly RP215-recognized IgG is a novel biomarker for cancer metastasis.
RP215 can be used to indicate poor prognosis and metastasis of epithelial cancers. Recently, we have reported that RP215 can be used to indicate poor prognosis and metastasis of lung adenocarcinoma . In this study, our results significantly revealed that RP215 have a potential application for indicating poor prognosis and metastasis of breast cancer.
In summary, we have uncovered that RP215-recognized IgG was specifically overexpressed in many epithelial lineage cancer cells, especially enriched in epithelial CSCs. Importantly, the IgG promotes cancer adhesion, invasion and self-renewal shall be of paramount importance in order to develop novel cancer therapeutic strategy directly against the cancer-derived IgG.
MATERIALS AND METHODS
Normal epithelial cancer and soft-tissue microarray (TMA) were purchased from ShanXi ChaoYin Biotechnology Co., Ltd., (Xi’an, China). The breast cancer TMA contained 45 pair of primary breast cancers and its metastasis cancers in lymph node (the details are available from). Paraffin-embedded samples of human breast cancer tissues were from the Department of Pathology, Beijing 301 Hospital (Beijing, China).
Antigen retrieval was conducted by immersing slides in Tris-EDTA buffer (pH 9.0) at 120°C for 5 min. Sections were pre-incubated with 3% H2O2 for 10 minutes and blocked in PBS plus 10% normal goat serum for 20 min. The sections were incubated with primary antibodies including RP215 (gifted by Prof. Gregory Lee), anti-p63 (Gene Tech), anti-CD44v6 (Invitrogen, California, USA), anti-CD24 (Invitrogen) and anti-CK5/6 (Dako Cytomation) overnight at 4°C according to the manufactures’ recommendations. After thorough washing, sections were exposed to Envision System horseradish peroxidase (DakoCytomation) for 20 minutes, sections were visualized with 0.05% 3, 3′-diamino-benzidine.
SDS-PAGE and western blotting
Whole-cell extracts were prepared in cell lysis buffer (10 mM Tris-HCl, 1% Triton-X 100, 1% sodium deoxycholate, 0.1% sodium dodecyl sulfate [SDS], 0.15 M NaCl, with protease inhibitor cocktail from Roche Applied Science [Indianapolis, IN]). Proteins were resolved by 12.5% SDS–polyacrylamide gel electrophoresis (PAGE) after denaturation with heat. The objective bands were cut and subjected to trypsin digestion after stained with Coomassie brilliant blue. Following digestion, mixtures of peptide fragments were subjected to MALDI-TOF MS analysis. Western blotting analysis was performed complying with standard procedures. Goat anti-human IgG (gamma chain specific) polyclonal antibody from Sigma Chemical (St. Louis, MO), RP215 (generated by Gorge Lee group), and biotinylated elderberry bark sialyl-lectin antibody (Vector Laboratories, California) were the primary antibodies. Following incubation with IRDye 700-conjugated anti-mouse and IRDye 800-conjugated anti-goat or IRDye 800–conjugated streptavidin secondary antibodies (Rockland Immunochemicals, Gilbertsville, PA), signals was detected on an Odyssey Infrared Imager (Li-COR Biosciences, Lincoln, NE).
Cell proliferation assay
Cell growth was determined by a CCK8 colorimetric growth assay. Briefly, cells were cultured in 96-well plates (2 × 103 cells per well) in complete medium till confluence. Each day, cell growth was determined by adding 10 μl CCK8 solution in 100 μl DMEM with 10% FBS for 2 h at 37°C, and then the absorbance was measured with a 450-nm filter. This study was done in triplicate.
Colony formation assay
Cells were seeded into each well of 6-well plates (200 cells per well). 1 week later, the cells were stained with 0.1% crystal violet to assess colony formation. Colonies containing >40 cells were counted. This study was done in triplicate.
In vitro wound-healing assay
The scratch method was applied to evaluate cell migration. MDA-MB-231 cells (1 × 105) were grown to confluence on 24-well plates in DMEM (1 ml per well) with 2% FBS. After 24 h, a scratch was introduced with a yellow pipette tip. Cells were further cultured for 24 h or 48 h, and then areas refilled by migrating MDA-MB-231 cells were documented. Images of four selected areas were captured and analyzed every 24 h until the wound was healed. This study was done in triplicate.
Transwell migration and matrigel invasion assays
Transwell insert chambers with an 8 μm porous membrane (BD Biosciences, Billerica, MA) were used for the migration assay. For invasion assay, Costar transwells (Corning, Lowell, MA) coated with Matrigel (BD Biosciences) was used. Cells were added to the top chamber in serum-free medium, and the bottom chamber was filled with medium containing 10% FBS. Cells were incubated for 24 h or 48 h at 37°C in a humidified 5% CO2 atmosphere. Cells in the top chamber were removed by a cotton-tipped swab, and the migrated cells were stained with crystal violet. They were then visualized under a phase-contrast microscope and photographed. These studies were done in triplicate.
Cells were fixed with 4% paraformaldehyde, permeabilized with 0.1% Triton X-100/PBS for 5 min. After blocking with 2% FBS in PBS, cells were incubated with the primary antibodies against IgG, CK18, vimentin, or microtubulin for 1 h at room temperature. Secondary antibodies were goat anti-mouse or anti-rabbit labeled with Alexa 488 or TRITC (Jackson ImmunoResearch Laboratories, Inc.) for 1 h. Nuclei were counterstained with 4, 6-diamidino-2-phenylindole (Sigma). Confocal images were acquired with a TCS S2 microscope adapted to a DMIRBE inverted microscope (Leica Microsystems, Inc.).
Single-cell suspensions of cancer cells were suspended at a density of 10,000 cells/ml in DMEM medium containing 2% B27 (Invitrogen Ltd., Paisley, Scotland), 20 ng/ml epidermal growth factor and 10 ng/ml basic fibroblast growth factor (Peprotech, Ness-Ziona, Israel), and seeded into ultra low-attachment 24-well plates (1 ml per plate). After cultured for 1 week, the cells was collected and transferred on a collagen coated dish in cell culture medium (containing10% FBS). After approximately 48 hours, mammospheres adhered in these conditions were stained with methyl blue and counted under low magnification. This study was done in triplicate.
Assay of clone formation and division abilities of single cells
Both of IgG+ and IgGlow/− single cancer cell was sorted into 96-well plates (1 cell per well) by FACS, and culture in complete medium, then the number of clone formation was monitored. For assay of division abilities of single cell, the single cell clones of IgG+ or IgGlow/− cell was continuously cultured and the number of cell passage was determined for 35 days.
Quantitative RT-PCR (qRT-PCR)
qRT-PCR was carried out on 25 ng cDNA samples using platinum SYBR Green Master mix (Applied Biosystems, Carlsbad, CA). Assays were run in triplicate on the ABI Prism 7900HT system. Primers used for CDH1, MMP-2, and MMP-9 amplification were as follows: CDH1, 5′-TGCCCCCAATACCCCAGCGT-3′ (forward), 5′-TCCCTGTCCAGCTCAGCCCG-3′ (reverse); MMP-2, 5′-GACCA-TGCGGAAGCCACGCT-3′ (forward), 5′-CACCAGTGCCTGGGGCGAAG-3′ (reverse); MMP-9, 5′-GAGCCACGGCCTCCAACCAC-3′ (forward), 5′-GAG TCCAGCTTGCGGGGCAG-3′ (reverse). To ensure equal loading of cDNA into reverse-transcription reactions, 18S ribosomal mRNA was amplified using the following primers: 5′-GGAAGGGCACCACCAGGAGT-3′ (forward), 5′-TGCAGCCCCGGACATCTAAG-3′ (reverse). Data were extracted from the linear range of amplification. All quantifications were normalized to the endogenous control (18sRNA).
The siRNAs against Ig gamma chain constant region (siRNA1 and siRNA2) and the control RNA (NC) (siRNA1: 5′-GGUGGACAAGACAGUUGAG-3′, siRNA 2: 5′-AGUGCAAGGUCUCCAACAA-3′, NC: 5′-UUCUCCGAACGUGUCACGU-3′) purchased from Shanghai GenePharma Corporation, China. Cell density was adjusted to 2 × 106/350 μl. The knockdown efficiency of IgG was checked by Western blot.
NOD/SCID mice were used to assess the in vivo stem cell properties of the IgGhigh MDA-MB-231 cells compared to the IgGlow MDA-MB-231 cells. BALB/c nude mice were used to evaluate both of the metastasis properties of the IgGhigh MDA-MB-231 cells and tumor proliferation ability of MDA-MB-231 cells that treated by siRNA for IgG heavy chain. 5-week-old healthy female NOD/SCID and BALB/c nude mice were purchased from Vital River Laboratories (Beijing, China). All animals were used for in vivo experiments in accordance with the approved institutional guidelines of the People’s Republic of China Ministry of Health and by protocols approved by the Animal Care and Use Committee of Peking University Health Science Center. The mice were allowed to acclimate for 1 week after arrival.
To the analysis of tumor initiating abilities using a few cancer cells, we have performed the tumorigenicity assay using both cultural MDA-MB-231 cells and the MDA-MB-231 cells purified from the graft tumor, respectively. The cultural MDA-MB-231 cells were stained using RP215, and IgG+ or IgGlow/− cells was sorted by FACS. 500 IgG+ or IgGlow/− cells was suspended in 50 μl of a 1:1 mix of PBS and Matrigel (BD Biosciences, Bedford, MA, USA), then were transplanted subcutaneously into the mammary fat pads of 5-week-old NOD/SCID mice (Vitalriver, Beijing, China). After 5–8 weeks, the NOD/SCID mice were sacrificed and the number of tumor formed was measured. A portion of each fat pad injected was fixed in formalin and embedded in paraffin for histological analysis. H&E staining was performed.
To analysis of tumor metastasis abilities of MDA-MB-231 cells to liver in BALB/c nude mice, 1.0 × 106 cancer cells in 50 μl PBS were injected subcutaneously into the mammary fat pads. Six weeks after transplantation, the mice were sacrificed and dissected. The livers were weighed, measured, and fixed with 10% buffered formalin and embedded in paraffin for histological analysis.
3D cell culture
Rat-tail type I collagen was purchased from BD Biosciences. The pH of the collagen solution was adjusted to 7.4 with 1 N NaOH, cellular mixtures were made by adding MDA-MB-231 cells prepared in normal culture medium to the collagen solution; cell concentrations were adjusted to 1 × 106 cells/ml. The collagen solution becomes a gel after incubation for 1 hour at 37°C .
All data were analyzed with GraphPad Prism software and presented as a mean ± standard error of the mean. Statistical significance was determined by the two-tailed unpaired t-test with a significance level of 0.05. The Pearson correlation coefficients of IgG compared to that of CD44v6 was analyzed via Matlab software (Mathworks).
ACKNOWLEDGMENTS AND FUNDING
We thank Dalong Ma and Yanhui Yin, Department of Immunology, Peking University Health Science Center for their help; Qihua He and Lan Yuan Medical and Health Analysis Center, Peking University Health Science Center for their assistance in subcellular localization by confocal microscopy. This work was supported by grants from the National Nature Science Foundation of China (No. 81272237, No. 91229102, No. 81320108020) and Natural Science Foundation of Beijing (No. 7112082). We thank Walter Pagel from Scientific Publication at the University of Texas MD Anderson Cancer Center for editorial review of the manuscript.
CONFLICTS OF INTEREST
The authors declare no conflict of interest.
1. Qiu X, Yang G. Chinese J.Immunol. 1996; 5:296.
2. Qiu X, Zhu X, Zhang L, Mao Y, Zhang J, Hao P, Li G, Lv P, Li Z, Sun X, Wu L, Zheng J, Deng Y, Hou C, Tang P, Zhang S, et al. Human epithelial cancers secrete immunoglobulin g with unidentified specificity to promote growth and survival of tumor cells. Cancer research. 2003; 63:6488-6495.
3. Li M, Tang M and Deng X. [Positive immunoglobulin A expression in human epithelial carcinoma cell lines]. Zhonghua zhong liu za zhi [Chinese journal of oncology]. 2001; 23:451-453.
4. Geng LY, Shi ZZ, Dong Q, Cai XH, Zhang YM, Cao W, Peng JP, Fang YM, Zheng L and Zheng S. Expression of SNC73, a transcript of the immunoglobulin alpha-1 gene, in human epithelial carcinomas. World journal of gastroenterology. 2007; 13:2305-2311.
5. Babbage G, Ottensmeier CH, Blaydes J, Stevenson FK and Sahota SS. Immunoglobulin heavy chain locus events and expression of activation-induced cytidine deaminase in epithelial breast cancer cell lines. Cancer research. 2006; 66:3996-4000.
6. Huang J, Sun X, Mao Y, Zhu X, Zhang P, Zhang L, Du J and Qiu X. Expression of immunoglobulin gene with classical V-(D)-J rearrangement in mouse brain neurons. The international journal of biochemistry & cell biology. 2008; 40:1604-1615.
7. Chen Z and Gu J. Immunoglobulin G expression in carcinomas and cancer cell lines. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2007; 21:2931-2938.
8. Kang BY, Hu C, Prayaga S, Khaidakov M, Sawamura T, Seung KB and Mehta JL. LOX-1 dependent overexpression of immunoglobulins in cardiomyocytes in response to angiotensin II. Biochemical and biophysical research communications. 2009; 379:395-399.
9. Chen Z, Huang X, Ye J, Pan P, Cao Q, Yang B, Li Z, Su M, Huang C and Gu J. Immunoglobulin G is present in a wide variety of soft tissue tumors and correlates well with proliferation markers and tumor grades. Cancer. 2010; 116:1953-1963.
10. Niu N, Zhang J, Sun Y, Wang S, Sun Y, Korteweg C, Gao W and Gu J. Expression and distribution of immunoglobulin G and its receptors in an immune privileged site: the eye. Cellular and molecular life sciences : CMLS. 2011; 68:2481-2492.
11. Zhu X, Wu L, Zhang L, Hao P, Zhang S, Huang J, Zheng J, Liu Y, Li W, Zhang Y, Zhou C, Zhang Y, Yin CC and Qiu X. Distinct regulatory mechanism of immunoglobulin gene transcription in epithelial cancer cells. Cellular & molecular immunology. 2010; 7:279-286.
12. Qiu X, Sun X, He Z, Huang J, Hu F, Chen L, Lin P, You MJ, Medeiros LJ and Yin CC. Immunoglobulin gamma heavy chain gene with somatic hypermutation is frequently expressed in acute myeloid leukemia. Leukemia. 2013; 27:92-99.
13. Li X, Ni R, Chen J, Liu Z, Xiao M, Jiang F and Lu C. The presence of IGHG1 in human pancreatic carcinomas is associated with immune evasion mechanisms. Pancreas. 2011; 40:753-761.
14. Zheng J, Huang J, Mao Y, Liu S, Sun X, Zhu X, Ma T, Zhang L, Ji J, Zhang Y, Yin CC and Qiu X. Immunoglobulin gene transcripts have distinct VHDJH recombination characteristics in human epithelial cancer cells. The Journal of biological chemistry. 2009; 284:13610-13619.
15. Zhang S, Mao Y, Huang J, Ma T, Zhang L, Zhu X, Zheng J, Wu L, Yin CC and Qiu X. Immunoglobulin gene locus events in epithelial cells of lactating mouse mammary glands. Cellular and molecular life sciences : CMLS. 2010; 67:985-994.
16. Huang J, Sun X, Gong X, He Z, Chen L, Qiu X and Yin CC. Rearrangement and expression of the immunoglobulin mu-chain gene in human myeloid cells. Cellular & molecular immunology. 2014; 11:94-104.
17. Hu F, Zhang L, Zheng J, Zhao L, Huang J, Shao W, Liao Q, Ma T, Geng L, Yin CC and Qiu X. Spontaneous production of immunoglobulin M in human epithelial cancer cells. PloS one. 2012; 7:e51423.
18. Yang B, Ma C, Chen Z, Yi W, McNutt MA, Wang Y, Korteweg C and Gu J. Correlation of immunoglobulin G expression and histological subtype and stage in breast cancer. PloS one. 2013; 8:e58706.
19. Zhang L, Hu S, Korteweg C, Chen Z, Qiu Y, Su M and Gu J. Expression of immunoglobulin G in esophageal squamous cell carcinomas and its association with tumor grade and Ki67. Human pathology. 2012; 43:423-434.
20. Liang PY, Li HY, Zhou ZY, Jin YX, Wang SX, Peng XH and Ou SJ. Overexpression of immunoglobulin G prompts cell proliferation and inhibits cell apoptosis in human urothelial carcinoma. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2013; 34:1783-1791.
21. Lee G, Laflamme E, Chien CH and Ting HH. Molecular identity of a pan cancer marker, CA215. Cancer biology & therapy. 2008; 7:2007-2014.
22. Lee G. Cancer cell-expressed immunoglobulins: CA215 as a pan cancer marker and its diagnostic applications. Cancer biomarkers : section A of Disease markers. 2009; 5:137-142.
23. Lee G and Ge B. Cancer cell expressions of immunoglobulin heavy chains with unique carbohydrate-associated biomarker. Cancer biomarkers : section A of Disease markers. 2009; 5:177-188.
24. Lee G and Parastoo A. Peptide mapping and glycoanalysis of cancer cell-expressed glycoproteins CA215 recognized by RP215 monoclonal antibody. J Carbohydr Chem. 2012; 30:10-30.
25. Lee G, Chu RA and Ting HH. Preclinical assessment of anti-cancer drugs by using RP215 monoclonal antibody. Cancer biology & therapy. 2009; 8:161-166.
26. Lee G and Ge B. Inhibition of in vitro tumor cell growth by RP215 monoclonal antibody and antibodies raised against its anti-idiotype antibodies. Cancer immunology, immunotherapy : CII. 2010; 59:1347-1356.
27. Prater MD, Petit V, Alasdair Russell I, Giraddi RR, Shehata M, Menon S, Schulte R, Kalajzic I, Rath N, Olson MF, Metzger D, Faraldo MM, Deugnier MA, Glukhova MA and Stingl J. Mammary stem cells have myoepithelial cell properties. Nature cell biology. 2014; 16:942-950, 941-947.
28. Ricardo S, Vieira AF, Gerhard R, Leitao D, Pinto R, Cameselle-Teijeiro JF, Milanezi F, Schmitt F and Paredes J. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype. Journal of clinical pathology. 2011; 64:937-946.
29. Jaggupilli A and Elkord E. Significance of CD44 and CD24 as cancer stem cell markers: an enduring ambiguity. Clinical & developmental immunology. 2012; 2012:708036.
30. Dang TT, Prechtl AM and Pearson GW. Breast cancer subtype-specific interactions with the microenvironment dictate mechanisms of invasion. Cancer research. 2011; 71:6857-6866.
31. Afify A, Purnell P and Nguyen L. Role of CD44s and CD44v6 on human breast cancer cell adhesion, migration, and invasion. Experimental and molecular pathology. 2009; 86:95-100.
32. Jin F, Zhao L, Guo YJ, Zhao WJ, Zhang H, Wang HT, Shao T, Zhang SL, Wei YJ, Feng J, Jiang XB and Zhao HY. Influence of Etoposide on anti-apoptotic and multidrug resistance-associated protein genes in CD133 positive U251 glioblastoma stem-like cells. Brain research. 2010; 1336:103-111.
33. Kim YS, Jung MJ, Ryu DW and Lee CH. Clinicopathologic characteristics of breast cancer stem cells identified on the basis of aldehyde dehydrogenase 1 expression. Journal of breast cancer. 2014; 17:121-128.
34. Crum CP and McKeon FD. p63 in epithelial survival, germ cell surveillance, and neoplasia. Annual review of pathology. 2010; 5:349-371.
35. Arpino G, Wiechmann L, Osborne CK and Schiff R. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocrine reviews. 2008; 29:217-233.
36. Won Jeong K, Chodankar R, Purcell DJ, Bittencourt D and Stallcup MR. Gene-specific patterns of coregulator requirements by estrogen receptor-alpha in breast cancer cells. Molecular endocrinology. 2012; 26:955-966.
37. Boissan M and Lacombe ML. [NM23, an example of a metastasis suppressor gene]. Bulletin du cancer. 2012; 99:431-440.
38. Wang GS, Zhu H and Bi SJ. Pathological features and prognosis of different molecular subtypes of breast cancer. Molecular medicine reports. 2012; 6:779-782.
39. Meng H, Chen R, Li W, Xu L and Xu L. Correlations of TOP2A gene aberrations and expression of topoisomerase IIalpha protein and TOP2A mRNA expression in primary breast cancer: a retrospective study of 86 cases using fluorescence in situ hybridization and immunohistochemistry. Pathology international. 2012; 62:391-399.
40. Holliday DL and Speirs V. Choosing the right cell line for breast cancer research. Breast cancer research : BCR. 2011; 13:215.
41. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X and Perou CM. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast cancer research : BCR. 2010; 12:R68.
42. Han J, Yong B, Luo C, Tan P, Peng T and Shen J. High serum alkaline phosphatase cooperating with MMP-9 predicts metastasis and poor prognosis in patients with primary osteosarcoma in Southern China. World journal of surgical oncology. 2012; 10:37.
43. Liu J, Tan Y, Zhang H, Zhang Y, Xu P, Chen J, Poh YC, Tang K, Wang N and Huang B. Soft fibrin gels promote selection and growth of tumorigenic cells. Nature materials. 2012; 11:734-741.
44. Shackleton M, Quintana E, Fearon ER and Morrison SJ. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell. 2009; 138:822-829.
45. Liu Y, Liu D, Wang C, Liao Q, Huang J, Jiang D, Shao W, Yin CC, Zhang Y, Lee G and Qiu X. Binding of the monoclonal antibody RP215 to immunoglobulin G in metastatic lung adenocarcinomas is correlated with poor prognosis. Histopathology. 2015; 67:645-653.
46. Rhee S. Fibroblasts in three dimensional matrices: cell migration and matrix remodeling. Experimental & molecular medicine. 2009; 41:858-865.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.